| CRDL Stock | | | CAD 3.81 0.24 6.72% |
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as
signals in board of governors.
At this time, Cardiol Therapeutics'
Capital Lease Obligations is very stable compared to the past year. As of the 4th of June 2024,
Capital Expenditure Coverage Ratio is likely to grow to 419.03, while
Net Invested Capital is likely to drop about 33.4
M. At this time, Cardiol Therapeutics'
Net Interest Income is very stable compared to the past year. As of the 4th of June 2024,
Interest Income is likely to grow to about 2.9
M, while
Depreciation And Amortization is likely to drop about 177
K.
Cardiol Therapeutics Class Company Z Score Analysis
Cardiol Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
Cardiol Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiol Therapeutics is extremely important. It helps to project a fair market value of Cardiol Stock properly, considering its historical
fundamentals such as Z Score. Since Cardiol Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiol Therapeutics' historical
financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiol Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
In accordance with the company's disclosures, Cardiol Therapeutics Class has a Z Score of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the
Health Care industry. The z score for all Canada stocks is 100.0% higher than that of the company.
Cardiol Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cardiol Therapeutics from analyzing Cardiol Therapeutics' financial statements. These drivers represent accounts that assess Cardiol Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cardiol Therapeutics' important valuation drivers and their relationship over time.
Cardiol Fundamentals
About Cardiol Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiol Therapeutics Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiol Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Cardiol Therapeutics Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Cardiol Stock
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics'
future performance.
For an informed investment choice regarding Cardiol Stock, refer to the following important reports: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.